Effect of 0.5% Povidone Iodine on the Oropharyngeal/Nasopharyngeal Samples Of COVID-19 Patients: A Double-Blind Placebo-Controlled Randomized Controlled Trial.

ttar Pradesh University Of Medical Sciences0 个研究点目标入组 32 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1. Patients infected with SARS-CoV-2 on the day one of admission before administration of any routine treatment.
•2. Patientsâ?? age should be 18 years and above at the time of enrollment, considering he/she can provide informed legal consent.
•3. Patients presented with mild to moderate COVID-19 illness.
•4. Patients presented to the hospital within 10 days of symptom onset.

•1. Patients infected with SARS-CoV-2 admitted in the hospital for more than one day and on routine treatment for COVID-19.
•2. Any patient who has severe illness debilitating the patient to provide consent as well as adopt the study procedure.
•3. Patients less than 18 years of age at the time of enrollment.
•4. Patients already using oral/intra-nasal antiseptic.
•5. Any patient with known thyroid disorders.
•6. Pregnant and lactating women.
•7. Patients who disagree to consent.

发起方

ttar Pradesh University Of Medical Sciences